Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement

EP: 1.Exploring the Landscape Surrounding Light Chain Amyloidosis

EP: 2.Expert Perspectives on Differentiating Signs and Symptoms in AL Amyloidosis Diagnosis

EP: 3.Exploring Diagnostic Approaches for Patients with Light Chain Amyloidosis

EP: 4.Current Treatment Landscape for AL Amyloidosis

EP: 5.Unmet Needs and Treatment Considerations in Managing AL Amyloidosis

EP: 6.Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis

EP: 7.Optimizing Treatment Management Strategies in AL Amyloidosis with CD38-Directed mAbs

Now Viewing

EP: 8.Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement

EP: 9.The Role of Cardiac Staging in Patients with AL Amyloidosis

EP: 10.Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL

EP: 11.AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis

EP: 12.Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

EP: 13.The Potential Role of CAR T Therapy in AL Amyloidosis

EP: 14.NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

EP: 15.Looking Ahead: Future Perspectives on AL Amyloidosis

This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.

Panelists examine the challenge of managing patients with light chain (AL) amyloidosis with cardiac involvement, a crucial factor in outcomes. Up to 80% of patients experience cardiac complications, significantly impacting overall survival. The intricate pathophysiology involves stiff hearts requiring higher filling pressures, which complicates fluid management. Patients with nephrotic syndrome and autonomic neuropathy face additional complexities, leading to massive third spacing and hypotension.

The discussion highlights the sensitivity of these patients to variations in heart rate and afterload reduction. Standard treatments for atrial fibrillation and heart failure, such as beta blockers or angiotensin-converting enzyme inhibitors, pose challenges and may exacerbate patients’ condition. The intricacies of fluid balance and the delicate management of these patients emphasize the unmet medical needs within this challenging patient population.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.